Ezetimibe/rosuvastatin
Combination of | |
---|---|
Ezetimibe | Hypolipidemic agent |
Rosuvastatin | Statin |
Clinical data | |
Trade names | Ridutrin, Lipocomb, Rosuzet, others[1][2] |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a cholesterol lowering combination medication.[5] In some countries it is sold as a kit or a pack containing two distinct pills.[6][1] It is also available in the form of a composite package containing the two separate pills.[3]
The combination was approved for medical use in the United States in March 2021.[4]
Medical uses[]
Ezetimibe/rosuvastatin is indicated as an adjunct to diet in people with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); and alone or as an adjunct to other LDL-C-lowering therapies in people with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.[7]
References[]
- ^ a b "Rosuvastatin international". Drugs.com. 3 February 2020. Retrieved 17 February 2020.
- ^ a b "Ezetimibe/rosuvastatin: List of nationally authorised medicinal products" (PDF). European Medicines Agency (EMA). 21 March 2018. PSUSA/00010271/201707. Retrieved 17 February 2020.
- ^ a b c "TGA eBS - Product and Consumer Medicine Information Licence".
- ^ a b "Roszet: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 March 2021.
- ^ "Ridutrin SmPC" (PDF). Medicines Data Bank. 30 May 2019. Retrieved 17 February 2020.
- ^ "Rosuzet Composite Pack". NPS MedicineWise. 8 January 2020. Retrieved 17 February 2020.
- ^ https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213072Orig1s000ltr.pdf
External links[]
- "Ridutrin (rosuvastatin zinc/ezetimibe) Public Assessment Report Scientific discussion" (PDF). NL/H/3017/001-003/DC.
Categories:
- Combination drugs
- Hypolipidemic agents
- Cardiovascular system drug stubs